Which medication may help to reduce intraocular pressure in central retinal artery occlusion?

Which medication may help to reduce intraocular pressure in central retinal artery occlusion?

• A. Latanoprost
• B. Acetazolamide
• C. Mannitol
• D. Timolol

Answer: (D)

Lowering intraocular pressure can improve retinal perfusion in central retinal artery occlusion because ocular perfusion pressure is roughly the mean arterial pressure minus the intraocular pressure. When IOP falls, the perfusion pressure across the retinal circulation increases, potentially helping to push more blood through the occluded or compromised artery. Timolol is a topical nonselective beta-blocker that reduces aqueous humor production by acting on the ciliary body. This directly lowers intraocular pressure with a rapid, local effect when used as eye drops, making it a practical option to begin increasing retinal perfusion pressure in the acute setting of CRAO. Other options have different profiles: prostaglandin analogs like latanoprost mainly increase outflow and can have a slower onset; systemic carbonic anhydrase inhibitors (acetazolamide) or osmotic agents (mannitol) lower IOP but require systemic administration or IV use and carry more systemic considerations, though they can be very effective in rapid IOP reduction. The topical timolol, by providing a quick, straightforward reduction in IOP, fits as a first-line topical measure to help improve retinal perfusion in this context.

Lowering intraocular pressure can improve retinal perfusion in central retinal artery occlusion because ocular perfusion pressure is roughly the mean arterial pressure minus the intraocular pressure. When IOP falls, the perfusion pressure across the retinal circulation increases, potentially helping to push more blood through the occluded or compromised artery.

Timolol is a topical nonselective beta-blocker that reduces aqueous humor production by acting on the ciliary body. This directly lowers intraocular pressure with a rapid, local effect when used as eye drops, making it a practical option to begin increasing retinal perfusion pressure in the acute setting of CRAO.

Other options have different profiles: prostaglandin analogs like latanoprost mainly increase outflow and can have a slower onset; systemic carbonic anhydrase inhibitors (acetazolamide) or osmotic agents (mannitol) lower IOP but require systemic administration or IV use and carry more systemic considerations, though they can be very effective in rapid IOP reduction. The topical timolol, by providing a quick, straightforward reduction in IOP, fits as a first-line topical measure to help improve retinal perfusion in this context.